CGEN-15051

**CGEN-15051** is a novel Fc fusion protein developed by Compugen as an immunomodulatory candidate for autoimmune diseases. It demonstrated initial validation in preclinical models, specifically reducing disease severity in the collagen-induced arthritis (CIA) model of rheumatoid arthritis when tested at a commercial lab specializing in autoimmune animal models.[2][3][5][7] Related candidate CGEN-15031 was tested in multiple sclerosis models, indicating a platform approach for Fc fusion proteins targeting autoimmune indications.[2][7] No further clinical development or human data are reported in available sources.[2][3][5][7]